• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

暴发性1型糖尿病:最新研究进展与未来展望

Fulminant type 1 diabetes: recent research progress and future prospects.

作者信息

Imagawa Akihisa, Tachibana Megumi

机构信息

Department of Internal Medicine (I), Osaka Medical College, 2-7 Daigaku-cho, Takatsuki, 569-8686 Japan.

出版信息

Diabetol Int. 2020 Sep 16;11(4):336-341. doi: 10.1007/s13340-020-00466-2. eCollection 2020 Oct.

DOI:10.1007/s13340-020-00466-2
PMID:33088640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7538502/
Abstract

To clarify the clinical and etiological characteristics of fulminant type 1 diabetes, we reviewed data from patients who had developed type 1 diabetes following anti-programmed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) therapy, and research on pancreatic beta cells derived from induced pluripotent stem (iPS) cells from patients with fulminant type 1 diabetes. As determined from the disease classifications and clinical and genetic characteristics, anti-PD-1/PD-L1 therapy-related type 1 diabetes includes both fulminant type 1 diabetes and acute-onset type 1 diabetes. Using insulin-positive cells derived from iPS cells, beta-cell fragility to inflammatory cytokines, but not its regeneration failure, was observed in fulminant type 1 diabetes. Moreover, severe hyperglycemia was reported as a risk factor of sudden death or cardiac arrest at disease onset, diffusion-weighted magnetic resonance imaging was suggested as an additional tool for making a diagnosis, and the locus was genetically associated with fulminant type 1 diabetes. To fully understand fulminant type 1 diabetes, it is important to clarify the molecular mechanisms step by step through multifaceted approaches such as through analyses of the genetic factors, clinical features, histological findings, and cell biology. The careful and detailed study of patients is a great means for clarifying the etiology and pathophysiology of the disease.

摘要

为阐明暴发性1型糖尿病的临床和病因学特征,我们回顾了接受抗程序性细胞死亡蛋白1/程序性细胞死亡配体1(抗PD-1/PD-L1)治疗后发生1型糖尿病的患者的数据,以及对暴发性1型糖尿病患者诱导多能干细胞(iPS细胞)来源的胰腺β细胞的研究。根据疾病分类以及临床和遗传特征确定,抗PD-1/PD-L1治疗相关的1型糖尿病包括暴发性1型糖尿病和急性起病型1型糖尿病。在暴发性1型糖尿病中,利用iPS细胞来源的胰岛素阳性细胞,观察到β细胞对炎性细胞因子的脆弱性,但未观察到其再生失败。此外,严重高血糖被报道为疾病发作时猝死或心脏骤停的危险因素,扩散加权磁共振成像被建议作为一种辅助诊断工具,并且该位点与暴发性1型糖尿病存在遗传关联。为全面了解暴发性1型糖尿病,通过多方面的方法逐步阐明分子机制很重要,例如通过分析遗传因素、临床特征、组织学发现和细胞生物学。对患者进行仔细和详细的研究是阐明该疾病病因和病理生理学的重要手段。

相似文献

1
Fulminant type 1 diabetes: recent research progress and future prospects.暴发性1型糖尿病:最新研究进展与未来展望
Diabetol Int. 2020 Sep 16;11(4):336-341. doi: 10.1007/s13340-020-00466-2. eCollection 2020 Oct.
2
Genetics of fulminant type 1 diabetes.暴发性1型糖尿病的遗传学
Diabetol Int. 2020 Sep 21;11(4):315-322. doi: 10.1007/s13340-020-00468-0. eCollection 2020 Oct.
3
Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.在非小细胞肺癌患者接受纳武利尤单抗治疗期间,出现胰岛素依赖型糖尿病急剧发作,且抗谷氨酸脱羧酶抗体滴度阳性。
Cancer Immunol Immunother. 2018 Sep;67(9):1417-1424. doi: 10.1007/s00262-018-2203-3. Epub 2018 Jul 11.
4
Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research.暴发型 1 型糖尿病的发病机制:基因、病毒和免疫机制,以及患者来源的诱导多能干细胞在未来研究中的应用。
J Diabetes Investig. 2019 Sep;10(5):1158-1164. doi: 10.1111/jdi.13091. Epub 2019 Jul 8.
5
Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in on Chromosome 12q13.13 Associated With Susceptibility to Fulminant Type 1 Diabetes.全基因组关联研究证实了 HLA 的强烈作用,并鉴定出染色体 12q13.13 上的 与暴发性 1 型糖尿病易感性相关的变异。
Diabetes. 2019 Mar;68(3):665-675. doi: 10.2337/db18-0314. Epub 2018 Dec 14.
6
Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.PD-1 和 PD-L1 抑制剂引起的糖尿病:胰腺内分泌和外分泌表型的描述。
Acta Diabetol. 2019 Apr;56(4):441-448. doi: 10.1007/s00592-018-1234-8. Epub 2018 Oct 4.
7
Risk factors for sudden death and cardiac arrest at the onset of fulminant type 1 diabetes mellitus.暴发性1型糖尿病发病时猝死和心脏骤停的危险因素。
Diabetol Int. 2015 Dec 29;7(3):281-288. doi: 10.1007/s13340-015-0247-6. eCollection 2016 Sep.
8
Immune checkpoint therapy and type 1 diabetes.免疫检查点疗法与1型糖尿病
Diabetol Int. 2016 Jul 5;7(3):221-227. doi: 10.1007/s13340-016-0276-9. eCollection 2016 Sep.
9
The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.由检查点抑制剂引起的糖尿病的多面性。
Acta Diabetol. 2019 Dec;56(12):1239-1245. doi: 10.1007/s00592-019-01402-w. Epub 2019 Aug 19.
10
Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.人脂肪间充质干细胞预防免疫检查点阻断诱导的 1 型糖尿病。
Diabetologia. 2022 Jul;65(7):1185-1197. doi: 10.1007/s00125-022-05708-3. Epub 2022 May 5.

引用本文的文献

1
Pregnancy-associated fulminant type 1 diabetes mellitus: Two case reports and literature review.妊娠相关暴发性1型糖尿病:两例报告及文献综述。
Exp Ther Med. 2025 Jul 23;30(3):179. doi: 10.3892/etm.2025.12929. eCollection 2025 Sep.
2
Improved acid-driven inhibition of effector T cell function by a pHLIP variant-conjugated PD-L1.通过一种与pHLIP变体偶联的PD-L1改善酸驱动的效应T细胞功能抑制
Sci Rep. 2025 Apr 18;15(1):13422. doi: 10.1038/s41598-025-98135-4.
3
Immune checkpoint inhibitor-related diabetes mellitus associated with high signal intensity in diffusion-weighted magnetic resonance imaging of the pancreas at an early clinical stage.免疫检查点抑制剂相关糖尿病在临床早期阶段与胰腺扩散加权磁共振成像中的高信号强度相关。
Hormones (Athens). 2025 Jan 17. doi: 10.1007/s42000-025-00629-3.
4
Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.病例报告:日本患者免疫检查点抑制剂诱导的 1 型糖尿病中存在强烈 GAD 抗体阳性和 HLA 易感单倍型-DRB1*04:05-DQB1*04:01
Front Endocrinol (Lausanne). 2024 May 22;15:1407192. doi: 10.3389/fendo.2024.1407192. eCollection 2024.
5
Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes.鉴定 hsa_circRNA_100632 作为暴发性 1 型糖尿病的新型分子生物标志物。
Front Immunol. 2023 Feb 23;14:1075970. doi: 10.3389/fimmu.2023.1075970. eCollection 2023.
6
Regulation of Viral Infection in Diabetes.糖尿病中病毒感染的调控
Biology (Basel). 2021 Jun 13;10(6):529. doi: 10.3390/biology10060529.
7
Fulminant type 1 diabetes: nationwide effort to elucidate genetics, etiology, and pathogenesis since 2000.暴发性1型糖尿病:自2000年以来阐明遗传学、病因学和发病机制的全国性努力。
Diabetol Int. 2020 Sep 29;11(4):342-343. doi: 10.1007/s13340-020-00469-z. eCollection 2020 Oct.

本文引用的文献

1
Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.派姆单抗诱发暴发性1型糖尿病,初诊时C肽持续存在。
Endocrinol Diabetes Metab Case Rep. 2020 Apr 29;2020. doi: 10.1530/EDM-19-0152.
2
Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report.抗程序性细胞死亡蛋白-1 治疗期间 Graves 病和 1 型糖尿病的同时发生:病例报告。
J Diabetes Investig. 2020 Jul;11(4):1006-1009. doi: 10.1111/jdi.13212. Epub 2020 Feb 16.
3
Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.纳武利尤单抗致暴发性 1 型糖尿病伴 C 肽水平急剧下降
J Diabetes Investig. 2020 May;11(3):748-749. doi: 10.1111/jdi.13143. Epub 2019 Oct 6.
4
A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.一名患有与纳武单抗相关的暴发性1型糖尿病的患者,其血清C肽水平在高血糖初次检测时保持正常。
Intern Med. 2019 Oct 1;58(19):2825-2830. doi: 10.2169/internalmedicine.2780-19. Epub 2019 Jun 27.
5
Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research.暴发型 1 型糖尿病的发病机制:基因、病毒和免疫机制,以及患者来源的诱导多能干细胞在未来研究中的应用。
J Diabetes Investig. 2019 Sep;10(5):1158-1164. doi: 10.1111/jdi.13091. Epub 2019 Jul 8.
6
T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors.免疫检查点抑制剂给药后发生1型糖尿病患者胰腺胰岛中的T淋巴细胞浸润
Diabetes Care. 2019 Jul;42(7):e116-e118. doi: 10.2337/dc18-2518. Epub 2019 May 10.
7
A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.一例纳武利尤单抗致黑素瘤患者急性发作 1 型糖尿病。
Curr Oncol. 2019 Feb;26(1):e115-e118. doi: 10.3747/co.26.4130. Epub 2019 Feb 1.
8
Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy.抗程序性细胞死亡 1 抗体诱导的孤立性促肾上腺皮质激素缺乏症相关的暴发性 1 型糖尿病:自身免疫性内分泌病发病机制的探讨。
Endocr J. 2019 Apr 25;66(4):295-300. doi: 10.1507/endocrj.EJ18-0328. Epub 2019 Feb 27.
9
Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy.与抗程序性细胞死亡-1治疗相关的1型糖尿病的特征及临床病程
Diabetol Int. 2018 Jul 3;10(1):58-66. doi: 10.1007/s13340-018-0362-2. eCollection 2019 Jan.
10
Detailed Time Course of Decline in Serum C-Peptide Levels in Anti-Programmed Cell Death-1 Therapy-Induced Fulminant Type 1 Diabetes.抗程序性细胞死亡蛋白1治疗诱导的暴发性1型糖尿病患者血清C肽水平下降的详细时间进程
Diabetes Care. 2019 Mar;42(3):e40-e41. doi: 10.2337/dc18-1673. Epub 2019 Jan 18.